Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-20 20:31 |
6-K
|
English | ZIP • 254.5 KB | ||
| 2023-10-18 10:45 |
Communiqué de presse : Des données de ph III présentées au Congrès de l’ISPAD m…
|
French | PDF • 243.6 KB | ||
| 2023-10-18 10:45 |
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow …
|
English | PDF • 225.6 KB | ||
| 2023-10-17 20:18 |
Sanofi: Information concerning the total number of voting rights and shares - S…
|
English | PDF • 145.1 KB | ||
| 2023-10-17 20:18 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - SEPTE…
|
French | PDF • 121.9 KB | ||
| 2023-10-13 16:00 |
Communiqué de presse : Des données de phase IIb de dernière heure sur l’amlitel…
|
French | PDF • 193.1 KB | ||
| 2023-10-13 16:00 |
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show p…
|
English | PDF • 184.3 KB | ||
| 2023-10-11 12:05 |
6-K
|
English | ZIP • 48.2 KB | ||
| 2023-10-04 07:00 |
Communiqué de presse : Sanofi et Teva annoncent une collaboration exclusive pou…
|
French | PDF • 197.6 KB | ||
| 2023-10-04 07:00 |
Press Release: Sanofi and Teva announce exclusive collaboration to deliver infl…
|
English | PDF • 196.2 KB | ||
| 2023-10-03 07:30 |
Communiqué de presse : Sanofi annonce un accord sur un vaccin contre les souche…
|
French | PDF • 201.0 KB | ||
| 2023-10-03 07:30 |
Press Release: Sanofi announces agreement for potential first-in-class vaccine …
|
English | PDF • 197.3 KB | ||
| 2023-09-27 12:06 |
6-K
|
English | ZIP • 59.7 KB | ||
| 2023-09-26 07:30 |
Communiqué de presse : La FDA accorde un examen prioritaire à Dupixent® (dupilu…
|
French | PDF • 199.9 KB | ||
| 2023-09-26 07:30 |
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophag…
|
English | PDF • 194.3 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
